Skip to main content
Publications
Phillips T, Lugtenburg P, Kalsekar A, Mutebi A, Wang A, Blaedel J, Kosa K , Martin S , Sacchi M, Kilavuz N, Thieblemont C. Improvements in patient-reported outcomes in relapsed or refractory large b-cell lymphoma patients treated with epcoritamab . Clin Lymphoma Myeloma Leuk. 2023 Nov 27;24(3):e78-e87.e. doi: 10.1016/j.clml.2023.11.005
Juliao P , Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, Tilson H, Covington D, Moore T, Marino R, Gilbride J, Liu A, Meizlik P, Petri M. Belimumab use during pregnancy: interim results of the belimumab pregnancy registry . Birth Defects Res Part A Clin Mol Teratol. 2023 Jan 15;115(2):188-204. doi: 10.1002/bdr2.2091
Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R , Morrison R, Doward L , Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory multiple Myeloma in the CARTITUDE-1 study . Clin Lymphoma Myeloma Leuk. 2022 Nov 7;16:54. doi: /10.1016/j.clml.2022.10.001
Spira A, Zhou X , Chen L, Gnanasakthy A , Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma . Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001
Richardson D , Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M , Odom D , Hollis K , Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application . Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7
Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L , Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer . Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x
Liede A, Mansfield CA , Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment . Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.
Dine JL , O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl . Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.
Police RL, Trask PC, Wang J, Olivares R, Khan SB , Abbe A, Colosia AD , Njue AI , Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis . Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008
Tennis P, Chan KA, Curkendall SN, Li DK, Mines D , Peterson C, Andrews EB, Calingaert B , Chen HY, Deshpande G, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ , Esposito DB. Topiramate use during pregnancy and major congenital malformations in multiple populations . Birth Defects Res Part A Clin Mol Teratol. 2015 Apr;103(4):269-75. doi: 10.1002/bdra.23357.
Njue A , Colosia A , Trask PC, Olivares R, Khan S , Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review . Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006
Colosia A , Njue A , Trask PC, Olivares R, Khan S , Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review . Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-55. doi: 10.1016/j.clml.2014.02.012